Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

114
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
114
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

98
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
98
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

69
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
69
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

19.9K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
19.9K
Cancer Prevention02:59

Cancer Prevention

8.7K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
8.7K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

12.0K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
12.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of different interchain linkers on biological activity of an anti-prostate cancer single-chain bispecific antibody.

Theoretical biology & medical modelling·2015
Same author

Lycopene inhibits neointimal hyperplasia through regulating lipid metabolism and suppressing oxidative stress.

Molecular medicine reports·2014
Same author

Nanochemistry-derived Bi2WO6 nanostructures: towards production of sustainable chemicals and fuels induced by visible light.

Chemical Society reviews·2014
Same author

Observing the role of graphene in boosting the two-electron reduction of oxygen in graphene-WO₃ nanorod photocatalysts.

Langmuir : the ACS journal of surfaces and colloids·2014
Same author

Inhibitory receptor immunoglobulin-like transcript 4 was highly expressed in primary ductal and lobular breast cancer and significantly correlated with IL-10.

Diagnostic pathology·2014
Same author

A large-scale lithography-free metasurface with spectrally tunable super absorption.

Nanoscale·2014

Related Experiment Video

Updated: Apr 5, 2026

CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis
10:40

CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis

Published on: April 25, 2022

3.0K

Relationship between gene polymorphisms and prostate cancer risk.

Qian-He Han1, Zhong-Jie Shan1, Jian-Ting Hu1

  • 1Department of Urology, People's Hospital of Zhengzhou, Zhengzhou, China.

Asian Pacific Journal of Tropical Medicine
|August 16, 2015
PubMed
Summary

The p27 V109G polymorphism is linked to reduced prostate cancer (Pca) risk. The p27-109G allele may protect against Pca by enhancing apoptosis and reducing cell proliferation.

Keywords:
Case–control studyLNcap cellsProstate cancerp27 V109G polymorphism

More Related Videos

miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

11.3K
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

17.3K

Related Experiment Videos

Last Updated: Apr 5, 2026

CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis
10:40

CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis

Published on: April 25, 2022

3.0K
miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

11.3K
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

17.3K

Area of Science:

  • Genetics
  • Oncology
  • Molecular Biology

Background:

  • Prostate cancer (Pca) is a significant health concern.
  • Genetic factors play a role in Pca development.
  • Understanding gene-polymorphism associations is crucial for risk assessment.

Purpose of the Study:

  • To investigate the relationship between specific genetic polymorphisms and Pca risk.
  • To explore the underlying molecular mechanisms of Pca development related to these genes.

Main Methods:

  • Genotyping of CYPl7 rs743572, p27 V109G, and AR gene CAG repeats in 70 Pca cases and 70 controls.
  • Case-control study using PCR-RFLP and STR-PCR techniques.
  • In vitro studies involving transfection of Pca LNcap cells with wild/mutant p27 genes, followed by MTT assay, flow cytometry, and Western blot analysis.

Main Results:

  • The p27 V109G polymorphism was significantly associated with Pca risk (P=0.030, OR=0.202).
  • The p27-109G allele showed a lower risk of Pca compared to the -109V allele (P=0.006, OR=0.285).
  • Transfection with both wild and mutant p27 genes increased apoptosis and decreased proliferation in LNcap cells, with mutant p27 having a stronger effect.

Conclusions:

  • The p27-109G allele is associated with higher p27 protein expression.
  • This allele may act as a protective factor against prostate cancer.
  • The p27 gene's role in regulating cell proliferation and apoptosis is critical in Pca.